Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Director/PDMR Shareholding

3 Dec 2008 11:59

RNS Number : 4632J
ABCAM Plc
03 December 2008
 



For immediate release

3 December 2008

ABCAM PLC

("Abcam" or "the Company")

ABCAM PLC SHARE INCENTIVE PLAN 

Directors' Dealings

On 7 November 2008 Abcam announced that as a result of transactions on 6 November 2008 by the Abcam plc Share Incentive Plan -"the Plan" - (an HMRC approved all employee share purchase plan adopted by the Company's shareholders at the Company's AGM on 3 November 2008), Jonathan Milner, Jeff Iliffe and Jim Warwick, Executive Directors of the Company, had each been awarded 649 "Free shares". The beneficial ownership of these shares will pass to the Executive Directors on 6 November 2011 subject to their continued employment with Abcam plc.

The final dividend of 4.56 pence per share which was approved at the AGM was paid on 28 November 2008. Pursuant to the terms of the Plan, on 2 December 2008, the dividend paid on the "Free shares" granted to the Executive Directors as detailed above was used to purchase additional shares at 475p each to be held on behalf of the Executive Directors in the Abcam plc Share Incentive Plan. These shares are as detailed below: 

Dividend shares  purchased

No of shares held in the

Plan on 2 December 2008

Including the dividend

shares

Jeff Iliffe

6

1,273

Jonathan Milner

6

1,273

Jim Warwick

6

1,273

For further information please contact:

Abcam
+ 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
 
Jeff Iliffe, Chief Financial Officer
www.abcam.com
 
 
 
Numis Securities
+ 44 (0) 20 7776 1500
Nominated Adviser - Michael Meade, Nick Westlake
Corporate Broking - James Black
 
 
 
Buchanan Communications
+ 44 (0) 20 7466 5000
Mark Court / Mary-Jane Johnson
 
 
 

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies headquartered in CambridgeUK, with a US office located in CambridgeMassachusetts and a Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of over 47,000 products, most of which are antibodies, from over 250 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs over 200 staff in its three operating companies.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSFXLFBVLBEFBZ
Date   Source Headline
1st Oct 20204:41 pmRNSTotal Voting Rights
25th Sep 20201:33 pmRNSDirector/PDMR Shareholding
18th Sep 20202:19 pmRNSBlock listing Interim Review
18th Sep 20207:54 amRNSDirector/PDMR Shareholding
14th Sep 20207:00 amRNSFull Year Results 2020
11th Sep 202010:34 amRNSNotice of Results
1st Sep 20207:52 amRNSTotal Voting Rights
4th Aug 202012:57 pmRNSTotal Voting Rights
23rd Jul 20207:00 amRNSChange of Adviser
23rd Jul 20207:00 amRNSFull Year Trading Update
2nd Jul 202010:11 amRNSTotal Voting Rights
16th Jun 202012:00 pmRNSDirectorate Change
1st Jun 20209:29 amRNSTotal Voting Rights
11th May 202011:00 amRNSStatement re Update on 2019 AGM Resolution Vote
1st May 202012:24 pmRNSTotal Voting Rights
22nd Apr 202010:11 amRNSHolding(s) in Company
21st Apr 20207:26 amRNSDirector/PDMR Shareholding
20th Apr 202010:19 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSCOVID-19 Update
14th Apr 202010:07 amRNSHolding(s) in Company
9th Apr 20205:33 pmRNSIssue of Shares
2nd Apr 20209:50 amRNSTotal Voting Rights
27th Mar 20203:37 pmRNSHolding(s) in Company
9th Mar 20207:00 amRNSInterim results for 6 months ended 31 Dec 2019
4th Mar 20207:00 amRNSAcquisition of Marker Gene Technologies
2nd Mar 20203:43 pmRNSTotal Voting Rights
2nd Mar 20208:00 amRNSBlock listing Interim Review
4th Feb 202010:49 amRNSTotal Voting Rights
30th Jan 20207:00 amRNSAbcam expands cell engineering capabilities
28th Jan 20202:31 pmRNSHolding(s) in Company
28th Jan 20202:29 pmRNSDirector/PDMR Shareholding
14th Jan 20207:00 amRNSAppointment of Chief Financial Officer
10th Jan 20207:00 amRNSHalf Year Trading Update
2nd Jan 20209:45 amRNSTotal Voting Rights
2nd Jan 20207:00 amRNSTransaction complete between Abcam and Expedeon
19th Dec 201910:05 amRNSHolding(s) in Company
4th Dec 20193:37 pmRNSHolding(s) in Company
2nd Dec 20193:25 pmRNSDirector/PDMR Shareholding
2nd Dec 20199:30 amRNSTotal Voting Rights
21st Nov 201911:42 amRNSHolding(s) in Company
14th Nov 20197:00 amRNSAbcam Capital Markets Event
13th Nov 20194:45 pmRNSResult of AGM
11th Nov 20197:00 amRNSAbcam to acquire proteomics & immunology business
6th Nov 20199:06 amRNSDirector/PDMR Shareholding
1st Nov 201910:55 amRNSTotal Voting Rights
2nd Oct 20194:28 pmRNSHolding(s) in Company
2nd Oct 20191:49 pmRNSDirector/PDMR Shareholding
1st Oct 20192:22 pmRNSTotal Voting Rights
30th Sep 20191:35 pmRNSAnnual Financial Report
26th Sep 20192:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.